Shares of Rocket Pharmaceuticals, Inc. surged 10% in pre-market trading on Friday following a landmark regulatory decision in the United States. The Food and Drug Administration (FDA) has approved Kresladi, a gene therapy for the treatment of severe Leukocyte Adhesion Deficiency-I (LAD-I), marking the first time a therapy has been authorized specifically for this rare and often fatal immune disorder.
Rocket Pharma shares rise on FDA approval for gene therapy
The FDA approved Kresladi for severe Leukocyte Adhesion Deficiency-I, marking the first treatment for the disorder. Shares rose 10% following the announcement.
Xurve View
洞察:
Xurve View
LAD-I is a condition that prevents white blood cells from reaching infection sites, leaving patients highly susceptible to life-threatening infections. Without a stem cell transplant, approximately 75% of untreated patients do not survive past the age of two. Kresladi is a one-time treatment that works by harvesting a patient’s own blood stem cells, genetically correcting the defective gene, and infusing the modified cells back into the body.











